Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, as treatment for IBS. METHODS: In two identically designed, phase 3, double-blind, placebo-controlled trials (TARGET 1 and TARGET 2), patients who had IBS without constipation were randomly assigned to either rifaximin at a dose of 550 mg or placebo, three times daily for 2 weeks, and were followed for an additional 10 weeks. The primary end point, the proportion of patients who had adequate relief of global IBS symptoms, and the key secondary end point, the proportion of patients who had adequate relief of IBS-related bloating, were assessed weekly. Adequate relief was defined as self-reported relief of symptoms for at least 2 of the first 4 weeks after treatment. Other secondary end points included the percentage of patients who had a response to treatment as assessed by daily self-ratings of global IBS symptoms and individual symptoms of bloating, abdominal pain, and stool consistency during the 4 weeks after treatment and during the entire 3 months of the study. RESULTS: Significantly more patients in the rifaximin group than in the placebo group had adequate relief of global IBS symptoms during the first 4 weeks after treatment (40.8% vs. 31.2%, P=0.01, in TARGET 1; 40.6% vs. 32.2%, P=0.03, in TARGET 2; 40.7% vs. 31.7%, P<0.001, in the two studies combined). Similarly, more patients in the rifaximin group than in the placebo group had adequate relief of bloating (39.5% vs. 28.7%, P=0.005, in TARGET 1; 41.0% vs. 31.9%, P=0.02, in TARGET 2; 40.2% vs. 30.3%, P<0.001, in the two studies combined). In addition, significantly more patients in the rifaximin group had a response to treatment as assessed by daily ratings of IBS symptoms, bloating, abdominal pain, and stool consistency. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Among patients who had IBS without constipation, treatment with rifaximin for 2 weeks provided significant relief of IBS symptoms, bloating, abdominal pain, and loose or watery stools. (Funded by Salix Pharmaceuticals; ClinicalTrials.gov numbers, NCT00731679 and NCT00724126.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Placebo-controlled studies of antibiotic (rifaximin) treatment in FGIDs and IBS have demonstrated significant reduction in bloating scores with rifaximin compared to placebo150–152.”
From The gut Microbiome in adult and pediatric functional gastrointestinal disorders (2019) · cites this paper as [151]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A short course of a non-absorbable antibiotic such as rifaximin has been shown to moderately improve the symptoms of irritable bowel syndrome (IBS), particularly bloating and flatulence.”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, it is likely that patients may require repeated courses of therapy, as trial evidence suggests the benefit diminishes by 12 weeks.189”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [189]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The sample size calculation was based on a one-sided α level of 0·0125 to account for two primary end points, an assumed placebo response rate of 40 % and a treatment difference of 10 % in responder rates based on previously published studies( 23 , 28 ). Further, accounting for a potential 10 % dropout rate and three interim analyses, 580 subjects in each group were required, totalling to 1740 sub”
From Effect of the probiotic strain Bifidobacterium animalis subsp. lactis , BB-12 ® , on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial (2015) · cites this paper as [23]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, treatments that change the microbiota, such as antibiotics or fecal microbiota transplant, 19,20 may be bene fi cial in a subset of patients with IBS.”
From Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis (2023) · cites this paper as [19]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Self-citationPimentel, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05902-6 · Cited by 669
Self-citationSmall intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499
Pimentel, M., Park, S., Mirocha, J., Kane, S. V., & Kong, Y. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-8-200610170-00004 · Cited by 466
Self-citationSharara, A. I., Aoun, E., Abdul-Baki, H., Mounzer, R., Sidani, S., & ElHajj, I. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00458.x · Cited by 344
Attar, A., Flourié, B., Rambaud, J., Franchisseur, C., Ruszniewski, P., & Bouhnik, Y. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70336-7 · Cited by 234
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Self-citation
Research works printed but not linked: 1
- El-Serag HB. Impact of irritable bowel syndrome: prevalence and effect on health- related quality of life. Rev Gastroenterol Disord 2003;3:Suppl 2:S3-S11.
Cited by
Items 901–1,000 of 1,000
Menozzi, A., Dall’Aglio, M., Quintavalla, F., Meucci, V., & Bertini, S. (2017) · Veterinary Record Case Reports · doi:10.1136/vetreccr-2016-000423
“…prescribed against traveller’s diarrhoea in humans, was also proven to be effective in several chronic intestinal diseases in human patients, such as IBD and irritable bowel syndrome associated with bacterial overgrowth (Huang and DuPont 2005, Majewski and others 2007, Pimentel et al., 2011).”
BackgroundCost Savings Associated With Rifaximin for Diarrhea-Predominant Irritable Bowel Syndrome
Pimentel, M., Schoenfeld, P., Purdy, M. C. H., Gilbert, C. J., & Magar, R. (2012) · The American Journal of Managed Care
Self-citationKonservative Therapie, Primär- und Sekundärprophylaxe der Divertikelkrankheit
Leifeld, L. (2017) · Springer eBooks · doi:10.1007/978-3-662-53549-3_8
Assessment of the Efficacy of Rifaximin in the Management of Irritable Bowel Syndrome (IBS)
Doffou, S., Anzouan-Kacou, K. H., Messou, E., Bangoura, D., Kouamé, D., Alassan, M. K., Assi, C., Bathaix, F. M. Y., ATTIA, A. K., & Lohoues, M. J. (2017) · Open Journal of Gastroenterology · doi:10.4236/ojgas.2017.710027
“Rifaximin received regulatory approval for the treatment of IBS-D in May 2015 [23].”
BackgroundInfluentialde Jongh, T. O. H. (2017) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-1922-0_22
Therapeutic Manipulation of Gut Microbiota
Ishiguro, E. E., Haskey, N., & Campbell, K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-810541-2.00007-5
Konservative Therapie der Divertikelkrankheit
Oestreich, R., Könemann, J., & Leifeld, L. (2018) · coloproctology · doi:10.1007/s00053-018-0277-1
TREATMENT OF IRRITABLE BOWEL SYNDROME: A REVIEW
Bikash, G., Dash, B., Sujata, P., & Bora, A. J. (2018) · Asian Journal of Pharmaceutical and Clinical Research · doi:10.22159/ajpcr.2018.v11i9.25953
Functional Gastrointestinal Disorders
Mayer, E. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00139-1
Persistent Gastrointestinal Symptoms in the Ill-Returning Traveler
Riddle, M. S., Shlim, D. R., & Connor, B. A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54696-6.00021-5
Postinfection irritable bowel syndrome
Marcellini, M. M., Barbaro, M. R., Cremon, C., & Barbara, G. (2018) · NeuroGastroLATAM Reviews · doi:10.24875/ngl.18000012 · Cited by 2
Archampong, T. N. A., & Nkrumah, K. N. (2014) · Changing Trends in Mental Health Care and Research in Ghana eBooks
Whorwell, P. J. (2013) · Wiley eBooks · doi:10.1002/9781118444689.ch13
Irritable bowel syndrome and probiotics place in therapeutic strategies
Aramă, Ș.-S. (2018) · Infectio ro · doi:10.26416/inf.56.4.2018.2188
Malagelada, C., & Malagelada, J. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-01117-8_10
Infections Associated With Irritable Bowel Syndrome
Gurunathan, S. V., & Grover, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-54843-4.00007-6
Yadav, S. (2020) · Journal of Medical Science And clinical Research · doi:10.18535/jmscr/v8i1.74
Behandlung des Reizdarmsyndroms
Loeliger, B. (2017) · pharma-kritik · doi:10.37667/pk.2016.1009
Microbiote et syndrome de l’intestin irritable : que faut-il savoir ? Perspectives thérapeutiques
Bazin, T. (2020) · Côlon & Rectum · doi:10.3166/cer-2020-0141
Colonic Conditions: Irritable Bowel Syndrome (IBS)
Koerner, C. P., & Sullivan, P. S. (2020) · Springer eBooks · doi:10.1007/978-3-319-65942-8_50 · Cited by 1
Schindler, V., Huellner, M. W., Murray, F. R., Schnurre, L., Becker, A. S., Bordier, V., & Pohl, D. (2020) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19162
“While a significant reduction of global IBS symptoms could be shown after therapy with Rifaximin in a previous study, 6 no preselection of SIBO diagnosis was performed there.”
Intestinal microbiota at functional intestinal disorders and celiac disease
Губергриц, Н. Б., Byelyayeva, N. V., Klochkov, O. Y., Фоменко, П. Г., Rachmetova, V. S., Цыс, А. В., & Voronin, K. O. (2020) · Modern Gastroenterology · doi:10.30978/mg-2020-4-51
Ткач, С. М., Dorofeev, A. E., & Kuzenko, Y. G. (2021) · Modern Gastroenterology · doi:10.30978/mg-2021-1-38
Síndrome del intestino irritable
Martínez, F. G., Pérez, C. P., Begazo, R. C., Delgado, A. Á., & Pérez, A. R. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70308-6 · Cited by 3
Ткач, С. М., Dorofeev, A. E., & Kuzenko, Y. G. (2021) · Modern Gastroenterology · doi:10.30978/mg-2021-2-21
Choe, S. C., & 이동호 (2012)
Irritable Bowel Syndrome-Strategies for Diagnosis and Management
Kassebaum-Ladewski, A. (2021) · Physician Assistant Clinics · doi:10.1016/j.cpha.2021.05.008
Li, H., Xiang, Y., Zhu, Z., Wang, W., Jiang, Z., Zhao, M., Cheng, S., Pan, F., Liu, D., Ho, R., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-820698/v1
Black, C. J. (2021) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
O’Donnell, S. T., Ross, R. P., Arendt, E. K., & Stanton, C. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00093-0
Konturek, P. C., & Zopf, Y. (2017) · MMW - Fortschritte der Medizin
A INFLUÊNCIA PSICOSSOMÁTICA EM PORTADORES DA SÍNDROME DO INTESTINO IRRITÁVEL
Duque, G. M., Pecemilis, I. S., Vargas, B. C. S., & Almeida, L. B. P. D. (2021) · Revista Científica da Faculdade de Medicina de Campos · doi:10.29184/1980-7813.rcfmc.350.vol.16.n2.2021 · Cited by 4
Qi, L., Yang, J.-W., Yan, S.-Y., Tu, J.-F., She, Y., Li, Y., Chi, L.-L., Wu, B.-Q., & Liu, C.-Z. (2021) · Research Square · doi:10.21203/rs.3.rs-1050148/v1
Economic Insecurity: Meaning and Measurement
Mughan, A. (2006) · The Knowledge Bank (The Ohio State University)
Strategies of human spatial cognition : cognitive and behavioural trade-offs.
Makány, T. (2009) · ePrints Soton (University of Southampton) · Cited by 2
Ho, E. Y. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734152606.793582238
Sherrill-Mix, S. A., Yang, M. X., Aldrovandi, G. M., Brenchley, J. M., Bushman, F. D., Collman, R. G., Dandekar, S., Klatt, N. R., Lagenaur, L. A., LANDAY, A. L., et al. (2021) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2021.0173
“35 James Virga from the National Cancer Institute reported results from the GUTCHEK study, where the effects of oral antibiotic rifaximin 36 on gut inflammation, immune activation, and microbiome were investigated in people living with HIV on long-term ART.”
Quigley, E. M. M. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch66 · Cited by 2
Louwies, T., & Meerveld, B. G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00037-2
Coffin, B. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717953474.793459042
İrritabl bağırsak sendromlu hastaların tedavisinde nane yağının etkinliği
YİĞİT, E., & Yılmaz, G. (2022) · Anatolian Journal of Health Research · doi:10.29228/anatoljhr.55777
Constipation, Irritable Bowel Syndrome, and Colic(Stomach Cramps)
Buttaravoli, P. M., & Leffler, S. M. (2012) · Elsevier eBooks · doi:10.1016/b978-0-323-07909-9.00067-2
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00018-2
Rubin, P. (2014) · Wiley eBooks · doi:10.1002/9781118932759.ch23
Abdominal Bloating and Visible Distension
Pimentel, M. (2016) · Wiley eBooks · doi:10.1002/9781119127437.ch68
Self-citationLembo, A. J. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.03.042
Self-citationAlpers, D. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717953474.793459515
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Talley, N. J. (2011) · Yearbook of Gastroenterology · doi:10.1016/j.ygas.2011.07.037
Funktionelle Magen-Darm-Erkrankungen
Keller, J., & Layer, P. (2014) · Humanmedizin kompakt · doi:10.1007/s40355-014-0024-y
Keller, J., & Layer, P. (2014) · Springer eBooks · doi:10.1007/978-3-642-54676-1_329-1
Kruis, W. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0448
Shi, Y., Ye, K., Chen, M., Xie, X., Fan, X.-Y., Xie, C.-R., Tao, Q., Hua, C., Wu, Q.-P., Jiang, X., et al. (2022) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2022.102145
Mechanism, Pathophysiology and Herbal Management-A Review on Irritable Bowel Syndrome
Wal, A., Wal, P., Verma, N., Rai, A. K., & Vatsha, P. (2022) · The Natural Products Journal · doi:10.2174/2210315512666220624163105
Song, K. H. (2022) · Springer eBooks · doi:10.1007/978-981-19-0120-1_18
Interferon and HPA Axis: Impact on Neuroimmunological Perturbations
Sharma, A., Singh, A. K., Kumar, V., & Prakash, H. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106090
Intestinal Microbiota, Alterations in Irritable Bowel Syndrome
Jeffery, I. B., Claesson, M. J., & O’Toole, P. W. (2012) · Springer eBooks · doi:10.1007/978-1-4614-6418-1_96-1
Interaction of Gut Microbiota with MedicationsPreprint
Liu, M., Xu, J., Jin, Q., & li, Y. (2022) · doi:10.22541/au.166523763.34733996/v1
Ткач, С. М., Dorofeev, A. E., & Kuzenko, Y. G. (2019) · Modern Gastroenterology · doi:10.30978/mg-2019-4-36
Gut Microbiota: Modulate its Complexity to Restore the Balance
Smithers, L. (2015) · EMJ Gastroenterology · doi:10.33590/emjgastroenterol/10310702
Rahman, M. S., Karim, M. R., & Haque, M. A. (2023) · Medicine Today · doi:10.3329/medtoday.v35i1.64940
Spanos, C. P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15648-9.00006-x
Lacy, B. E., & Cangemi, D. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13911-6.00029-3
Understanding small intestinal dysmotility symptoms: Bloating, distension, and gas
Azpiroz, F., & Malagelada, C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-13911-6.00034-7
Bacterial overgrowth in irritable bowel syndrome: prevalence, diagnosis, and treatment. Review
Ткач, С. М., & Dogotar, V. B. (2023) · Modern Gastroenterology · doi:10.30978/mg-2023-3-68
Go with your gut: targeting the microbiome for treatment of irritable bowel syndrome
Fung, S. S.-P. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-01027-8
CH4, H2S, and H2O: How Do They Relate to Microbiome-Driven IBS Pathogenesis?
Spencer, S. P. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08198-4
Keller, J., & Kandulski, A. (2023) · Die Gastroenterologie · doi:10.1007/s11377-023-00734-y
Symptoms, walking behaviors, and mobility of Thai patients after colorectal cancer surgery
Krisanabud, P. (2019) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/79566
The Role of Gut Bacteria in Functional Gastrointestinal Disorders
Damianos, J., & Shah, E. D. (2023) · Springer eBooks · doi:10.1007/978-3-031-46712-7_6
Sobin, W. H., & Sanvanson, P. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-48949-5_52
SHORT COURSE VS PROLONGED RIFAXIMIN THERAPY FOR POST INFECTIOUS IRRITABLE BOWEL SYNDROME
Salman, H., Razaq, S., Qaisar, A., Naz, S., Khan, A., & Khan, J. U. A. (2024) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/jptcp.v31i3.4785
Meteorism and abdominal distension
Joksimović, Z., Bastać, D., & Pavlović, S. (2024) · Timocki medicinski glasnik · doi:10.5937/tmg2401014j
Predictors of response to a dietary intervention in patients with irritable bowel syndrome
Pereyra, F., Schlottmann, F., Salvatori, C., Barbagelata, S., Steinberg, L., & Pereyra, L. (2024) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2024.502231
Serra, J., Aguilar, A., Barba, E., Ríos, C. C. D. L., Pravia, L. G., Martínez, V., & Falcón, B. S. (2024) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2024.04.072 · Cited by 1
THE ROLE OF LIFESTYLE-RELATED TREATMENTS FOR IRRITABLE BOWEL SYNDROME
Chamera-Cyrek, K., Sikora, O., Baran, J. M., Rowiński, D., Kuzminski, C., Podczerwińska, A., Prokop, D., Borek, M., Marzec, K., Jablonski, W., et al. (2024) · Archiv Euromedica · doi:10.35630/2024/14/4.410
Kamiya, T. (2024) · Springer eBooks · doi:10.1007/978-981-97-8410-3_16
Predictors of response to a dietary intervention in patients with irritable bowel syndrome
Pereyra, F., Schlottmann, F., Salvatori, C., Barbagelata, S., Steinberg, L., & Pereyra, L. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502231
Oxidative Stress State in Men with Irritable Bowel Syndrome
Hamad, M. A., Al-Ani, W. Y. M., & Ghazzay, H. (2025) · International Journal of Environmental Sciences · doi:10.64252/ys7fbb82
Gastroenterología Clínica y Traslacional: De la Fisiopatología al Tratamiento Personalizado
Menéndez, E. P. C., Colina, M. E. P., Ruiz, L. F. A., & Pinos, K. M. N. (2025) · doi:10.56470/978-9942-7428-2-7
Síndrome de intestino irritable y sobrecrecimiento bacteriano de intestino delgado
Villar-Chávez, A. S., & Ruiz-Romero, D. (2025) · Clínicas de gastroenterología de México · doi:10.24875/cgm.m25000008
It Is Time for a New IBS Paradigm
Kuon, C. (2025) · Global Advances in Integrative Medicine and Health · doi:10.1177/27536130251383554
Ke, W., Huang, S., Zhu, H., Tan, Q., Li, H., Liu, D., Zheng, F., Zhang, S., Lei, K., & Tang, H. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05095-3
Borkar, N. E., Gote, S., Salvi, P., & Khobragade, K. J. (2025) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20253696
Santos, J., Iordache, A., & Manolache, M. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003834
Colon targeted rifaximin pellets: optimization, in vivo study, and gamma scintigraphy assessment
Chaturvedi, A. K., SARA, U. V. S., & Rk, G. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-10231-0
Physiopathologie du syndrome de l’intestin irritable (SII)
Jouet, P. (2013) · Côlon & Rectum · doi:10.1007/s11725-013-0456-8 · Cited by 1
Zhang, S., Hong, G., Li, G., Qian, W., Jin, Y., & Hou, X. (2023) · Figshare · doi:10.6084/m9.figshare.22606078
Choudhary, A., Hait, A., Ganesan, S., Howlader, S., & Periasamy, P. (2025) · Research Square · doi:10.21203/rs.3.rs-8397380/v1
Diagnosis and treatment of irritable bowel syndrome with diarrhea: Key clinical considerations
Kassebaum-Ladewski, A., Orleck, K. D., & Skarbinski, K. F. (2026) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000001218
“…in patients with IBS-D, after a 2-week course of therapy, a signi fi cantly greater percentage of patients achieved adequate global IBS symptom relief with rifaximin versus placebo (40.7% vs. 31.7% [pooled data]; p < .001) for at least two of the fi rst 4 weeks posttreatment (Pimentel et al., 2011).”
InfluentialSoifer, L., Contreras, M. V., Man, F., & González-Flórez, A. (2026) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2025.11.003
Liu, Y., Yan, X., Yang, J.-H., Zhang, D., Fang, Y., Huang, J., Zhu, M., Li, L., Zhang, T., Zhang, Q.-H., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-105579
Zhou, J., Yin, G.-J., Liu, Y., & Ji, F. J. (2026) · Research Square · doi:10.21203/rs.3.rs-8650251/v1
Anumolu, A., van Rooyen, D., Kilburn, L. O., Thakur, E. R., van Tilburg, M. A. L., & Moshiree, B. (2026) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-026-00488-w
Personalized gastroenterology: irritable bowel syndrome
Sen, K., Majumder, S., Islam, M. S., Das, S. K., & Madhu, N. R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40483-2.00009-1
Chetia, D., & Borbora, S. (2026) · Journal of Datta Meghe Institute of Medical Sciences University · doi:10.4103/jdmimsu.jdmimsu_490_25
Metadata
- Authors
- Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Michigan Medicine (US)
- Bristol Hospital (US)
- University of North Carolina at Chapel Hill (US)
- Salix Pharmaceuticals (United States) (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-06
- Volume
- 364
- Issue
- 1
- Pages
- 22-32
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2149216059
- Cited by
- 1,036
- References
- 21
- Citations by year
- 2026: 51 · 2025: 46 · 2024: 36 · 2023: 56 · 2022: 51 · 2021: 65 · 2020: 56 · 2019: 51 · 2018: 65 · 2017: 74 · 2016: 87 · 2015: 70 · 2014: 95 · 2013: 73 · 2012: 87
- FWCI
- 106.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
- Keywords
- rifaximin, gut microbiota, bloating, abdominal pain, stool consistency, symptom relief, antibiotic therapy, IBS pathophysiology, TARGET trial, adverse events
- MeSH terms
- Rifaximin, Aged, Anti-Bacterial Agents, Diarrhea, Double-Blind Method, Female, Humans, Male, Middle Aged, Rifamycins, Abdominal Pain, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.